Business Context and Reporting Period
Company: Prestige Consumer Healthcare Inc. (PBH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2025
Business Overview: Prestige develops, manufactures, markets, and distributes over-the-counter (OTC) health and personal care products. The company operates through two segments: North American OTC Healthcare (84.4% of revenue) and International OTC Healthcare (15.6% of revenue). Major brands include Monistat, Fleet, Gaviscon, Chloraseptic, and Hydralyte. The company relies heavily on third-party manufacturers for production and distributes products through mass merchandisers, drug stores, and e-commerce channels.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Total Revenues | $1,137.8 million | $1,125.4 million | +1.1% |
| Gross Profit | $634.5 million | $624.4 million | +1.6% |
| Gross Margin | 55.8% | 55.5% | +30 bps |
| Operating Income | $336.8 million | $342.4 million | -1.6% |
| Net Income | $214.6 million | $209.3 million | +2.5% |
| Diluted EPS | $4.29 | $4.17 | +2.9% |
| Operating Cash Flow | $251.5 million | $248.9 million | +1.0% |
| Total Debt (Outstanding) | $1,000.0 million | $1,135.0 million | -$135.0 million |
| Cash and Equivalents | $97.9 million | $46.5 million | +$51.4 million |
Debt Structure: As of March 31, 2025, total indebtedness was $1.0 billion, consisting of $400 million in 5.125% Senior Notes due 2028 and $600 million in 3.750% Senior Notes due 2031. The company repaid its entire $135 million Term Loan balance during fiscal 2025. The revolving credit facility had $165.7 million in available capacity with no outstanding balance.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 1.1% to $1.14 billion. The International segment grew 6.4%, driven by Gastrointestinal and Dermatologicals, while the North American segment remained flat (+0.2%) due to declines in Cough & Cold offset by gains in Gastrointestinal.
- Impairment Charges: The company recorded $12.5 million in goodwill and tradename impairment charges in 2025, primarily related to non-strategic assets as the company shifts focus to core brands. This compares to zero impairment charges in 2024 (following significant impairments in 2023).
- Interest Expense: Net interest expense decreased significantly to $47.6 million from $67.2 million in 2024, reflecting the repayment of the Term Loan and a lower average cost of borrowing (4.7% vs. 5.4%).
- Share Repurchases: The company repurchased approximately 738,000 shares for $51.5 million under its share repurchase program, an increase from $25.0 million in the prior year.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted a deliberate strategic shift toward core brands, resulting in the impairment of non-strategic assets. The company continues to face supply chain challenges, particularly with eye care products, which have negatively impacted sales. Inflationary pressures on raw materials and labor remain a concern, though the company has managed to maintain gross margins through pricing and mix.
Key Risks and Contingencies:
- Supply Chain Dependence: The company relies on 98 third-party manufacturers. One supplier accounts for approximately 21% of gross revenues. Shortages in eye care products have already impacted results.
- Customer Concentration: Walmart (19%) and Amazon (14%) accounted for 33% of gross revenues in 2025. The company has no long-term contracts with these customers.
- Intangible Asset Impairment: Approximately 83% of total assets are goodwill and intangibles. Future declines in brand performance or increases in discount rates could trigger further impairment charges.
- Regulatory Environment: Products are subject to extensive FDA and international regulations. Non-compliance could lead to recalls or penalties.
Investor Verification Checklist
- Supplier Concentration: Verify the stability of the single supplier accounting for ~21% of revenue and the status of the $7.8 million in short-term loans extended to a supplier.
- Eye Care Shortages: Assess the duration and financial impact of ongoing shortages in eye care products (Clear Eyes, TheraTears) on future revenue guidance.
- Intangible Asset Valuation: Review the assumptions used in the annual impairment testing, specifically the discount rates and terminal growth rates for major brands like Monistat and Summer's Eve.
- Debt Covenants: Confirm continued compliance with the fixed charge ratio covenant (>1.0 to 1.0) given the high level of fixed debt obligations.
- Customer Mix: Monitor the trend of sales concentration with Walmart and Amazon and the potential impact of retailer inventory management strategies.